How will the multitude of emerging combination regimens pan out in MM?
Multiple myeloma treatment is rapidly evolving and the range of combination regimens is set to diversify. Janssen’s Darzalex has already proven a major success story, but what further opportunities await and how will BMS’ Empliciti and Sanofi’s isatuximab fit in? With Celgene’s Revlimid now considered a gold standard of care, and its follow-on agent Pomalyst/Imnovid gaining traction in the first-relapse setting, KOLs discuss the potential future growth and positioning of these IMiDs. Clarity is also offered on the evolving roles of the proteasome inhibitors Kyprolis (carfilzomib; Amgen) and Ninlaro (ixazomib; Takeda). Moreover, could the current excitement surrounding BCMA targeting agents translate to success for CAR-T therapy, BiTEs or ADCs?
Twelve of the world’s foremost KOLs from the US and EU offer candid insights on six marketed therapies and eight pipeline drugs.
Plus: Order the report and you’ll receive three quarterly FirstWord Therapy Trends Update Bulletins free!
“We're still riding that wave of daratumumab everywhere, adding daratumumab upfront, adding daratumumab in smoldering, and then likely in the next three to five years we need something post-daratumumab, because those patients are not being cured.”
US Key Opinion Leader
“BiTE is much simpler than CAR-T cells, we don’t need to wait weeks to obtain the drugs, and it’s cheaper. There is some toxicity, but that is also the case with CAR-T. So, will the future be BiTE or CAR-T cells? We don't really know, but I believe that this approach will have a future.”
US Key Opinion Leader
Marketed Therapies
Preregistration/Phase III Therapies
Phase I/II Therapies
KOLs from North America
KOLs from Europe
At FirstWord, we stand behind our reports. If you're not completely satisfied, we’ll refund your money. Guaranteed.
The world of pharma is ever changing and executives must always be up-to-date with new developments that could affect their own products, position and research. That is why FirstWord's guarantee to keep Therapy Trends clients up to date with Update Bulletins offers a real commercial advantage.
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
All Contents Copyright © 2021 Doctor's Guide Publishing Limited All Rights Reserved